ESR1 and breast carcinoma: 18F-FES PET/CT has been evaluated in numerous breast cancer clinical studies as a promising method for assessing in vivo ER expression, predicting response (to hormone therapy and adjuvant chemotherapy), evaluating effective ER blockade and assisting in individualized treatment strategy decisions43–47.